San Diego-based mostly Viking Therapeutics marked by itself as a significant competitor in the weight loss drug sector in February just after revealing promising facts from a mid-stage demo of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs whe